These patient case studies are part of a wider programme entitled ‘Hyperkalaemia in Cardiorenal Disease’. Watch these short videos, where Dr Burton presents a CKD patient at high risk of hyperkalaemia, and Dr Zieroth presents a HF patient with moderate to severe hyperkalaemia. After the videos have played, you can vote using the polls on how you would treat these patients. These cases, and their management strategy, will be discussed during a live roundtable. The panel will discuss emerging data and the changing landscape of medical management of hyperkalaemia. If you’d like to register for this roundtable, please enter your email after completing the polls.
This programme is supported by an unrestricted educational grant from AstraZeneca and brought to you by Radcliffe Medical Education.
Prof James Burton is Honorary Consultant Nephrologist and Professor of Renal Medicine and Associate Dean for Clinical Research at the University of Leicester, Leicester, UK. His principal research interests are the mechanisms underlying uraemic cardiovascular disease modification of cardiovascular risk in patients with end-stage renal disease and the identification and application of novel biomarkers.
In addition, Prof Burton is involved in the development and running of clinical trials; he is Chief Investigator for the NIHR funded NightLife trial investigating the impact of nocturnal dialysis on patient outcomes as well as the Kidney Research UK funded CONFIRM study exploring the utility of a novel cardiac magnetic resonance imaging (MRI) techniques in haemodialysis patients. Prof Burton is the independent Chair of two multi-centre NIHR Trial Steering Committees and sits on a number of others.
He is the current Chair of the UK Kidney Association Clinical Guidelines Committee and has himself chaired a number of UK guideline updates making sure that research translates into clinical practice.
Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St. Boniface Hospital in Winnipeg, CA.
She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba. She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Immediate Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She serves as Co-Chair of Canada’s largest annual heart failure meeting, HF Update and serves as Scientific Planning Committee Chair for the Canadian Cardiovascular Congress hosted by the Canadian Cardiovascular Society. She is currently President-elect of the Federation of Medical Women of Canada.
Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.